Predicting Post-Amnog Rebate Outcomes for Oncology Drugs

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.09.125
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Time to Reimbursement for Oncology Drugs in EU5

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Employment Outcomes for Recent Canadian Radiation Oncology Graduates

Current Oncology
Oncology
2019English

ReDO_DB: The Repurposing Drugs in Oncology Database

ecancermedicalscience
Cancer ResearchOncology
2018English

Potential Repurposing of Oncology Drugs for the Treatment of Alzheimer's Disease

BMC Medicine
Medicine
2013English

Diagnostic Biomarkers for Predicting Adverse Early Pregnancy Outcomes

BJOG: An International Journal of Obstetrics and Gynaecology
GynecologyObstetrics
2018English

Php293 - Orphan Drugs in Germany - Lessons Learned From Amnog, Best and Worst Practices and Strategic Implications

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Is the Proof of an Additional Benefit Under Amnog in Germany More Difficult for Certain Drugs Than for Other Ones?

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Reimbursement Decisions in Oncology Drugs: An International Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Towards Predicting Post-Editing Productivity

Machine Translation
LinguisticsArtificial IntelligenceLanguageSoftware
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy